Moleculin Biotech Inc.

1.27-0.0200-1.55%Vol 20.82K1Y Perf -6.52%
Jan 27th, 2023 15:43 DELAYED
BID1.25 ASK1.28
Open1.30 Previous Close1.29
Pre-Market- After-Market1.27
 - -  - -%
Target Price
8.67 
Analyst Rating
Strong Buy 1.00
Potential %
582.68 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
36.74 
Earnings Rating
Sell
Market Cap36.36M 
Earnings Date
24th Mar 2023
Alpha-0.03 Standard Deviation0.21
Beta1.80 

Today's Price Range

1.241.32

52W Range

0.81702.05

5 Year PE Ratio Range

-2.10-5.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-0.78%
1 Month
11.40%
3 Months
28.32%
6 Months
-25.29%
1 Year
-6.52%
3 Years
-76.22%
5 Years
-89.26%
10 Years
-

TickerPriceChg.Chg.%
MBRX1.27-0.0200-1.55
AAPL145.931.97001.37
GOOG100.711.55001.56
MSFT248.150.15000.06
XOM115.61-2.1500-1.83
WFC46.120.31000.68
JNJ168.23-0.6600-0.39
FB196.640.99000.51
GE83.232.09002.58
JPM140.320.34000.24
 
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.27-0.30-11.11
Q02 2022-0.25-0.244.00
Q01 2022-0.21-0.24-14.29
Q04 2021-0.21-0.1719.05
Q03 2021-0.20-0.1525.00
Q02 2021-0.20-0.195.00
Q01 2021-0.26-0.2023.08
Q03 2020-0.60-0.3640.00
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.280.00-
12/2022 FY-1.06-3.92Negative
3/2023 QR-0.290.00-
12/2023 FY-1.100.00-
Next Report Date24th Mar 2023
Estimated EPS Next Report-0.28
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume20.82K
Shares Outstanding28.63K
Shares Float27.96M
Trades Count157
Dollar Volume26.41K
Avg. Volume71.38K
Avg. Weekly Volume49.33K
Avg. Monthly Volume65.50K
Avg. Quarterly Volume99.32K

Moleculin Biotech Inc. (NASDAQ: MBRX) stock closed at 1.27 per share at the end of the most recent trading day (a -1.55% change compared to the prior day closing price) with a volume of 20.82K shares and market capitalization of 36.36M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. Moleculin Biotech Inc. CEO is Walter V. Klemp.

The one-year performance of Moleculin Biotech Inc. stock is -6.52%, while year-to-date (YTD) performance is 19.81%. MBRX stock has a five-year performance of -89.26%. Its 52-week range is between 0.817 and 2.05, which gives MBRX stock a 52-week price range ratio of 36.74%

Moleculin Biotech Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.59, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -35.70%, a ROC of -35.74% and a ROE of -39.42%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Moleculin Biotech Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Moleculin Biotech Inc.’s next earnings report date is 24th Mar 2023.

The consensus rating of Wall Street analysts for Moleculin Biotech Inc. is Strong Buy (1), with a target price of $8.67, which is +582.68% compared to the current price. The earnings rating for Moleculin Biotech Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Moleculin Biotech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Moleculin Biotech Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.54, ATR14 : 0.08, CCI20 : 58.61, Chaikin Money Flow : 0.08, MACD : 0.02, Money Flow Index : 54.14, ROC : 8.55, RSI : 52.38, STOCH (14,3) : 57.87, STOCH RSI : 0.46, UO : 50.87, Williams %R : -42.13), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Moleculin Biotech Inc. in the last 12-months were: Jonathan P. Foster (Option Excercise at a value of $0), Walter V. Klemp (Buy at a value of $83 498), Walter V. Klemp (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Moleculin Biotech Inc.

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with its focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

CEO: Walter V. Klemp

Telephone: +1 713 300-5160

Address: 5300 Memorial Drive, Houston 77007, TX, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

Bearish Bullish

60%40%

TipRanks News for MBRX

Sat, 12 Nov 2022 12:15 GMT Moleculin Biotech (MBRX) Receives a Buy from Maxim Group

- TipRanks. All rights reserved.

Wed, 28 Sep 2022 16:30 GMT Analysts Top Healthcare Picks: Ocugen (OCGN), Moleculin Biotech (MBRX)

- TipRanks. All rights reserved.

News

Stocktwits